Is retatrutide FDA-approved or available by prescription?

No. Retatrutide is investigational, is not FDA-approved, and is not available as a prescription medication. Lilly anticipates a regulatory submission as its Phase 3 package matures.

Is retatrutide better than tirzepatide or semaglutide?

TRIUMPH-1 produced a larger average weight-loss figure than the registrational trials of semaglutide and tirzepatide, but those were separate trials with different designs, durations, and populations. No head-to-head trial of retatrutide against tirzepatide or semaglutide has reported results.

Retatrutide TRIUMPH-1 Results Explained: 28.3% Weight Loss (2026)

The short version

On 21 May 2026, Lilly reported TRIUMPH-1 topline results: 28.3% mean weight loss at 80 weeks on 12 mg in adults with obesity/overweight without diabetes.
Lower doses still worked: 25.9% (9 mg) and 19.0% (4 mg), vs. ~2.2% placebo. A higher-BMI extension reached ~30.3% at 104 weeks.
It's a bigger number than semaglutide's and tirzepatide's registrational trials — but those were separate studies, not head-to-head.
Retatrutide is investigational and not FDA-approved. The trial showed weight and risk-marker changes, not proven reductions in heart attacks, stroke, cancer, or death.

What TRIUMPH-1 measured

TRIUMPH-1 is the pivotal general-obesity trial in Lilly's broader TRIUMPH Phase 3 program. It randomized 2,339 adults with obesity or overweight and at least one weight-related condition (but not diabetes) to once-weekly retatrutide 4 mg, 9 mg, 12 mg, or placebo, titrating up from 2 mg. The primary endpoint was percent change in body weight at 80 weeks.

TRIUMPH-1 — mean weight loss by dose

% of body weight at 80 weeks; 12 mg also shown for the 104-week higher-BMI extension

Data: Eli Lilly TRIUMPH-1 topline release, 21 May 2026 (efficacy estimand). The 104-week figure is a pre-specified extension subgroup with baseline BMI ≥35.

Lilly also reported that roughly 45% of participants on 12 mg achieved at least 30% weight loss — a threshold that begins to approach what bariatric surgery achieves, which is why the result drew so much attention.

How it compares to what's already approved

The headline number is larger than the registrational figures for the two leading approved options. But this is the most over-claimed part of the GLP-1 conversation, so be precise: these come from different trials, with different durations, doses, and patient populations. They are not a head-to-head comparison.

Registrational weight-loss figures — different trials

Highest studied dose, mean % weight loss (not a head-to-head comparison)

Sources: STEP-1 semaglutide 2.4 mg, 14.9% at 68 wks (NEJM 2021); SURMOUNT-1 tirzepatide 15 mg, 22.5% at 72 wks (NEJM 2022); TRIUMPH-1 retatrutide 12 mg, 28.3% at 80 wks (Lilly, 2026). Separate trials — not a head-to-head study. The only head-to-head among these molecules, SURMOUNT-5, compared tirzepatide and semaglutide (20.2% vs 13.7%).

Molecule	Class	Trial & dose	Mean loss	Status
Semaglutide	GLP-1	STEP-1, 2.4 mg	14.9%	FDA-approved
Tirzepatide	GIP/GLP-1	SURMOUNT-1, 15 mg	22.5%	FDA-approved
Retatrutide	GIP/GLP-1/glucagon	TRIUMPH-1, 12 mg	28.3%	Investigational

Why a "triple agonist" might do more

Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GIP and GLP-1). Retatrutide adds a third — glucagon — which is thought to increase energy expenditure on top of the appetite and satiety effects of the other two. More targets is the leading hypothesis for the larger figure, though the trial measured outcomes, not mechanism.

What TRIUMPH-1 did not show

Read this part. TRIUMPH-1 was a weight-loss trial. It reported weight change and improvements in risk markers — it did not demonstrate reductions in heart attacks, stroke, cancer, or death. Those questions are the job of the cardiovascular outcomes trial (TRIUMPH-3) and longer follow-up, which have not reported.

As with the whole class, weight tends to return after stopping treatment: discontinuation studies of semaglutide and tirzepatide showed participants regaining roughly two-thirds of lost weight within about a year. There is no reason yet to assume retatrutide is different. These are tools for ongoing management, not one-time cures.

Can you get retatrutide now?

No. Retatrutide is investigational and is not FDA-approved. It is not legally available as a prescription medication, and "research peptide" versions sold online are not quality-assured, not for human use, and carry real safety and legal risk. Lilly expects to file for approval as its Phase 3 package matures; additional readouts (TRIUMPH-2 in diabetes, TRIUMPH-3 in cardiovascular disease) are expected in 2026. For currently available, FDA-approved options, talk to a licensed clinician.

FAQ

How much weight did people lose on retatrutide?

An average of 28.3% on 12 mg at 80 weeks, 25.9% on 9 mg, and 19.0% on 4 mg, versus about 2.2% on placebo. A higher-BMI extension subgroup reached roughly 30.3% at 104 weeks.

Is retatrutide better than Ozempic, Wegovy, Mounjaro, or Zepbound?

Its trial figure is larger, but it has not been tested head-to-head against any of them, and it isn't approved. Cross-trial comparisons can mislead because populations and designs differ.

When could it be approved?

Lilly anticipates a regulatory submission as the data package matures, with more Phase 3 readouts expected in 2026. No approval date has been set.

Sources

Eli Lilly — TRIUMPH-1 topline Phase 3 results (21 May 2026).
The Pharmaceutical Journal; Pharmacy Times — TRIUMPH-1 coverage (May 2026).
STEP-1 (Wilding et al., NEJM 2021) — semaglutide 2.4 mg, 14.9%.
SURMOUNT-1 (Jastreboff et al., NEJM 2022) — tirzepatide 15 mg, 22.5%.
SURMOUNT-5 (Aronne et al., NEJM 2025) — head-to-head, tirzepatide 20.2% vs semaglutide 13.7%.